Benzinga | Nov 23, 2020 11:46AM EST

Zynerba Pharma Reports 2 Posters For Virtual Annual Meeting of the American Epilepsy Society Accepted

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and presentation details of two posters at the 2020 virtual annual meeting of the American Epilepsy Society (AES). The AES annual meeting is being held virtually from December 4th through December 8th, 2020. A copy of the posters will be made available on the Zynerba corporate website at the time of presentation at http://zynerba.com/publications/.

Title: ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Developmental and Epileptic Encephalopathies: An Openlabel Clinical Trial [BELIEVE (ZYN2-CL-25)]

Abstract #: 913882

Poster #: 983

Presentation Date: December 4, 2020

Title: Quality of Life and Caregiver Qualitative Assessments in Children with Developmental and Epileptic Encephalopathies Treated with ZYN002 (CBD) Transdermal Gel: BELIEVE (ZYN2-CL-025)

Abstract #: 913851

Poster #: 984

Presentation Date: December 4, 2020